Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Instituto Bioclon receives FDA approval for Anascorp to treat Centruroides scorpion sting

The U.S. Food and Drug Administration today approved Anascorp, the first specific treatment for a scorpion sting by Centruroides scorpions in the United States.

4 Aug 2011

FDA accepts MAP Pharmaceuticals' LEVADEX NDA for filing

MAP Pharmaceuticals, Inc. today announced that its New Drug Application (NDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA), with a goal date of March 26, 2012 under the Prescription Drug User Fee Act (PDUFA).

2 Aug 2011

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011

Colon cleansing can cause side effects like cramping, renal failure and death

Colon cleansing - it's been described as a natural way to enhance well-being, but Georgetown University doctors say there's no evidence to back that claim. In fact, their review of scientific literature, published today in the August issue of The Journal of Family Practice, demonstrates that colon cleansing can cause side effects ranging from cramping to renal failure and death.

1 Aug 2011

PA departments warn public regarding use of glass-bottled milk from Brunton Dairy in Aliquippa

The Pennsylvania departments of Health and Agriculture and the Allegheny County Health Department are advising the public of the possible health risks associated with products, specifically glass-bottled milk, from Brunton Dairy in Aliquippa, Beaver County.

30 Jul 2011

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of ORENCIA (abatacept) for the treatment of adults with moderate to severe rheumatoid arthritis.

30 Jul 2011

Cancer patients should stick to basic sun-protection guidelines, experts say

Summer often brings with it fun in the sun, but for cancer patients it also presents new challenges and the need for additional protection.

30 Jul 2011

Cadence confirms FDA dosing recommendations for OFIRMEV

Cadence Pharmaceuticals, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg.

29 Jul 2011

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes.

28 Jul 2011

Curis second quarter net loss increases to $4.9 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2011.

28 Jul 2011

Physiological instability precedes an hour before naturally occurring panic attacks

Panic attacks that seem to strike sufferers out-of-the-blue are not without warning after all, according to new research.

28 Jul 2011

FDA accepts peginesatide NDA for anemia associated with CKD

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

27 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Otsuka Canada Pharmaceutical Inc. (OCPI) announced today that Health Canada has issued a notice of compliance for SAMSCA (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

27 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BioDelivery Sciences International, Inc. announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.

25 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

Public disclosure of Bachmann's migraine condition raises much-needed awareness

University of Vermont Professor of Neurology and migraine expert Robert Shapiro, M.D., Ph.D., says U.S. Representative and presidential candidate Michele Bachmann's public disclosure of her migraine condition has brought much-needed awareness to this disabling, often-stigmatized disorder, which afflicts millions of Americans.

21 Jul 2011

Nausea News and Research

Further Reading

Instituto Bioclon receives FDA approval for Anascorp to treat Centruroides scorpion sting

FDA accepts MAP Pharmaceuticals' LEVADEX NDA for filing

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Colon cleansing can cause side effects like cramping, renal failure and death

PA departments warn public regarding use of glass-bottled milk from Brunton Dairy in Aliquippa

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Cancer patients should stick to basic sun-protection guidelines, experts say

Cadence confirms FDA dosing recommendations for OFIRMEV

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Curis second quarter net loss increases to $4.9 million

Physiological instability precedes an hour before naturally occurring panic attacks

FDA accepts peginesatide NDA for anemia associated with CKD

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Public disclosure of Bachmann's migraine condition raises much-needed awareness

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News